WO1999045120A2 - Attenuation de bacteries: matieres et methodes associees - Google Patents

Attenuation de bacteries: matieres et methodes associees Download PDF

Info

Publication number
WO1999045120A2
WO1999045120A2 PCT/GB1999/000675 GB9900675W WO9945120A2 WO 1999045120 A2 WO1999045120 A2 WO 1999045120A2 GB 9900675 W GB9900675 W GB 9900675W WO 9945120 A2 WO9945120 A2 WO 9945120A2
Authority
WO
WIPO (PCT)
Prior art keywords
salmonella
nucleic acid
polypeptide
gene
genes
Prior art date
Application number
PCT/GB1999/000675
Other languages
English (en)
Other versions
WO1999045120A3 (fr
Inventor
Timothy Stephen Wallis
Edouard Eugenievich Galyov
Michael William Wood
Original Assignee
Biotechnology And Biological Sciences Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotechnology And Biological Sciences Research Council filed Critical Biotechnology And Biological Sciences Research Council
Priority to EP99937942A priority Critical patent/EP1058732A2/fr
Publication of WO1999045120A2 publication Critical patent/WO1999045120A2/fr
Publication of WO1999045120A3 publication Critical patent/WO1999045120A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention concerns attenuation of bacteria and materials and methods relating thereto.
  • the present invention concerns vaccines for Salmonella and materials and methods relation thereto.
  • Salmonella comprises a genus of aerobic to facultatively anaerobic bacteria which cause a variety of effects in mammals: diarrhoea and/or abortion in some species of domestic livestock and enteric fever/food poisoning in humans. Some Salmonella serotypes cause predominantly enteric effects, others predominantly systemic effects.
  • Salmonella infection in young and elderly people can be particularly debilitating or even fatal. There remains a need for effective vaccines which are safe to use.
  • a characteristic feature of non-typhoid Salmonella infections in animals is an intense intestinal inflammatory and secretory response (acute inflammatory cell influx, fluid secretion) typical of enteritis.
  • intestinal inflammatory and secretory response acute inflammatory cell influx, fluid secretion
  • enteritis A characteristic feature of non-typhoid Salmonella infections in animals is an intense intestinal inflammatory and secretory response (acute inflammatory cell influx, fluid secretion) typical of enteritis.
  • enteropathogenic Salmonella strains are able to induce intact intestinal epithelia to recruit sub-epithelial neutrophils (PMNs) (McCormick et al . , 1995a, b).
  • PMNs sub-epithelial neutrophils
  • This Salmonella mediated transepithelial signalling to PMNs requires adhesion of Salmonella to the epithelial apical membrane and is dependent on protein synthesis in both bacteria and eukaryotic cells (McCormick et al . , 1993, 1995a) .
  • Salmonella mutants defective in the function of a type III secretion system encoded by the inv/spa/prg chromosomal loci were shown to be unable to elicit transepithelial signalling to PMNs (McCormick et al . , 1995a, b) .
  • the Inv/Spa secretion system of Salmonella is required for the ability of this pathogen to invade epithelial cells (for a review see Galan, 1996) .
  • SPI-1 pathogenicity island
  • SPI-2 a second pathogenicity island
  • SPI-2 was found to encode components of a second type III secretion system in Salmonella (Ochman et al . , 1996; Shea et al . , 1996).
  • SPI-2 is located at 30 centisome (Shea et al . , 1996) .
  • the genes located on the SPI-2 appear to be important for the development of systemic infection (Shea et al . , 1996) .
  • a Salmonella virulence-associated locus at 82 centisome was recently identified as a novel pathogenicity island, SPI-3.
  • SPI-3 encodes mtgCB genes essential for intramacrophage survival of the pathogen (Blanc-Potard and Groisman, 1997) .
  • Sip proteins Salmonella invasion proteins
  • Sop proteins Sop proteins
  • SopB protein that influences the translocation and intracellular activities of SopB (and possibly other Sop effector proteins) affect cellular responses leading to the influx of neutrophils into the intestinal epithelium and the induction of fluid secretion (Galyov et al . , 1997) .
  • the sip genes are constituents of SPI-1.
  • sopB is located on a large DNA fragment unique to the Salmonella chromosome and representing a new pathogenicity island, SPI-5 (this pathogenicity island has been previously referred to as SPI-4 by the present applicants eg in their UK Patent Application No. 9804809.3 filed on 6 March 1998) inserted adjacent to the t WA ⁇ ( serT) gene.
  • SPI-5 The structure of SPI-5 and its boundaries in relation to the sequence of the E. coli K-12 genome is described herein and data is provided indicating that SPI-5 encoded proteins are involved in the enteropathogenicity of Salmonella .
  • the SPI-5 is conserved in Salmonellae and maps at approximately 20 centisome of S . typhimurium chromosome. Sequence analysis reveals that the sopB-containing Salmonella-specific DNA fragment is flanked by DNA sequences sharing a significant sequence similarity with genes found in E. coli K-12, tRNA ⁇ ( serT) on one side and copS/copR on the other. Thus, this Salmonella-specific DNA fragment has features characteristic of "pathogenicity ' islands" .
  • SPI-5 pathogenicity island
  • S. dublin that mediates enteropathogenesis.
  • SPI-5 encoded genes are necessary for the enteropathogenic phenotype; SPI-5 is conserved in Salmonella, but not present in the other enteric bacteria tested in this study; SPI-5 is located immediately downstream of the serT gene encoding SPI-5 is also inserted between the serT and copR/copS genes.
  • the copS/copR genes map at 46 centisome on the E.
  • S. dublin 2229 compared to that of E. coli K-12.
  • this region of the S. dublin chromosome may represent a "hot spot" for recombination events with rearrangements of this area of the S. dublin chromosome occurring secondary to the acquisition of SPI-5 insertion-recombination events .
  • SPI-5 contains other genes associated with enteropathogenicity of S.duJlin.
  • the putative products of two of these genes, pipB and pipD have structural similarities to proteins from other bacterial species. The observed sequence similarities are suggestive of functions of these SPI-5 encoded proteins.
  • PipB is similar to HglK protein from Anahaena and Synechocystis spp. Since HglK appears to be required for localisation of heterocyst specific glycolipids (Black et al . , 1995), it is suggested that PipB has a role in glycolipid biogenesis.
  • PipD is structurally similar to dipeptidases from Lactobacillus spp and is suggested to be a peptidase of Salmonella having its target on the surface or inside the host cells.
  • SPI-5 was sequenced and, in addition to sopB, was found to contain five novel genes which the inventors have named pipA, pipB, pipC, pipD (pathogenicity island encoded proteins) and orfX.
  • pipA, pipB and pipD genes were mutated and the enteropathogenicity of the mutant strains assessed in bovine ileal ligated loops. The results of the study indicate that the pipA, pipB and pipD genes contribute to the enteropathogenicity of S.dublin.
  • sopA has also identified and characterised a previously unknown gene which they call sopA . Details relating to this new gene sopA are provided herein.
  • the present application provides a demonstration that sopA has translocation and intracellular activities which affect cellular responses leading to the influx of neutrophils into the intestinal epithelium and the induction of fluid secretion (akin to sopB) .
  • sopA has translocation and intracellular activities which affect cellular responses leading to the influx of neutrophils into the intestinal epithelium and the induction of fluid secretion (akin to sopB) .
  • sopA mutant S. dublin shows that sopA contributes to enteropathogenicity.
  • the sopA gene locates close to the SPI-1 pathogenicity island which embraces the structural components of the Inv/Spa secretion system.
  • the present application provides sequence information for sopA and instructions for its cloning and the construction of sopA mutants.
  • the present invention provides attenuated strains of Salmonella and attenuated strains of other enteric bacteria which have a homologue of a Salmonella protein/gene discussed herein; particularly provided are attenuated strains of Salmonella, Shigella and E. coli .
  • the present invention also provides prophylactic and therapeutic medicaments which contain as an effective agent one or more attenuated strains of Salmonella and other enteric bacteria (eg Shigella and E. coli) as hereby provided.
  • the present invention also provides use of one or more attenuated strains of Salmonella and other enteric bacteria (eg Shigella and E.
  • an attenuated strain of Salmonella as hereby provided in the preparation of a medicament comprising the attenuated strain (s) as an effective agent; the medicament being for the treatment of, or immunisation against, infection by Salmonella and other enteric bacteria (eg Shigella and E. coli) and/or for the treatment of, or immunisation against, infection with a pathogen different to the mutant pathogen employed for immunisation, nucleotide sequences for antigens of said different pathogen being carried and expressible by attenuated strains as hereby provided.
  • an attenuated strain of Salmonella as hereby provided may also be useful in relation to the treatment of other enteric bacteria (eg Shigella or E. coli ) .
  • an attenuated strain of other enteric bacteria eg Shigella or E. coli
  • enteric bacteria eg Shigella or E. coli
  • Salmonella and other enteric bacteria eg Shigella and E. coli
  • the present invention provides attenuated strains of Salmonella and attenuated strains of some other bacteria, particularly enteric bacteria such as Shigella and E. coli which carry a homologue of a Salmonella protein/gene discussed herein.
  • homologous versions in such other enteric bacteria will provide sites for achieving attenuation in accordance with the present invention.
  • Homologues of a Salmonella protein/gene discussed herein in other enteric bacteria having at least 20% overall sequence identity may be determined in accordance with standard techniques and by comparative analysis of sequences available on public data bases.
  • Attenuation is effected by alterations in one or more genes which contribute to the enteropathogenicity of an enteric bacteria eg Salmonella species so as to reduce the enteropathogenicity of the altered form of the bacteria eg Salmonella species in comparison to its wild type with or without affecting invasiveness .
  • Reduction in enteropathogenicity may be determined by measuring intestinal secretory response and/or intestinal inflammatory response (see later examples and Fig 4 and Fig 7) .
  • the attenuation in Salmonella may be effected by one or more alterations in one or more genes selected from sopD, sipA, sopA or a gene from within the pathogenicity island SPI-5 which comprises 6 genes including sopB and is flanked by the genes copS/copR and serT and wherein where there is an attenuation in the gene sopB of SPI-5 another said gene comprises an alteration.
  • Attenuation in other enteric bacteria eg Shigella and E. coli may be affected by alteration of genes in the subject bacteria equivalent to the Salmonella genes discussed herein.
  • Genes from within the SPI-5 pathogenicity island suitable for alteration may be selected from pipD, pipB, pipA.
  • the attenuation may be effected by an alteration in the gene sopD.
  • SopD was first sequenced by Ostrowski et al . , see J.Biol. Chem., 1989 264(26) pl5726-37, designated orf4 and identified as lying adjacent to SPI-1. No function was ascribed to sopD) .
  • the attenuation may be effected by an alteration in the gene sipA .
  • SipA was first described by Kaniga et al . , see J.Bacteriol . , 1995 177 p7078-7085 and lies within SPI-1. No function was ascribed to sipA) .
  • the attenuation may be effected by an alteration in the gene sopA as provided herein.
  • the attenuation may be effected by alterations in sopB and another gene as mentioned above.
  • the attenuation may be effected by alterations in sopD and sopB .
  • Alterations in both sopD and sopB is particularly and surprisingly advantageous in the context of attenuation.
  • the means of achieving attenuation as disclosed herein eg by alteration of one or more of sipA, sopA, pipD, pipB, pipA, sopD, sopB reduces enteropathogenicity.
  • a given strain of Salmonella may also be attenuated in accordance with known techniques to reduce systemic pathogenicity.
  • the attenuation of systemic pathogenesis may be achieved by curing of virulence plasmid (Wallis, T.S., et al . , 1995) or by altering one or more genes involved in the aromatic amino acid biosynthetic pathway (Jones, P.J., et al., 1991 Vaccine 9, 29-34).
  • a medicament comprising as an effective agent an attenuated strain of Salmonella or other enteric bacteria as discussed above may comprise, in addition, one or more physiologically acceptable carriers such as excipients, buffers, stabilisers, adjuvants or other materials known to those skilled in the art . Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material will depend on the route of administration. Examples of techniques and protocols mentioned above can be found in Remington' s Pharmaceutical Sciences, 16th edition, Osol, A. (ed) , 1980. Such a medicament may comprise one or more different effective agents eg the medicament may be a combination vaccine for use in relation to a variety of pathogens .
  • a said medicament may be administered alone or in combination with other treatments, either simultaneously or sequentially, dependent upon the condition to be treated.
  • the medicaments of the present invention are preferably given to an individual in a "prophylactically effective amount” or a “therapeutically effective amount” (as the case may be, although prophylaxis may be considered therapy) , this being sufficient to show benefit to the individual .
  • a “prophylactically effective amount” or a “therapeutically effective amount” as the case may be, although prophylaxis may be considered therapy
  • the actual amount administered, and rate and time-course of administration will depend on the nature and severity of the condition being treated. Prescription of treatment, eg decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors.
  • Attenuated Salmonella strains and other enteric bacteria are provided in an isolated and/or purified form, ie substantially pure. This may include being in a composition where it represents at least about 90% active ingredient, more preferably at least about 95%, more preferably at least about 98%. As stated above, however a composition may include inert carrier materials or other pharmaceutically and physiologically acceptable excipients.
  • the medicament may be formulated for administration by injection (cutaneous, subcutaneous or intravenous) or for mucosal administration eg via the oral, rectal, nasal, or genital routes.
  • the Salmonella genome or the genome of other enteric bacteria may itself provide the immunogen or it may contain a heterologous gene insert expressing an immunogenic protein.
  • the present invention can be employed to provide attenuated strains of Salmonella and other enteric bacteria (eg Shigella and E. coli ) for use as safe multivalent vaccines against a variety of foreign pathogens or other antigens for use in man and domestic animals.
  • the attenuated strains can also be employed to provide vaccines against medical conditions such as cancer, by inserting a nucleotide sequence encoding a tumour antigen, for instance, into the genome of an enteric bacterium.
  • the attenuated Salmonella may be an altered form of any serotype of Salmonella enterica subspecies enterica.
  • the attenuated Salmonella may be an altered strain of Salmonella typhimurium, Salmonella enteri tidis, Salmonella dublin or Salmonella choleraesuis .
  • Salmonella strains are available from the National Collection of Type Cultures, Central Public Health Lab, Collindale Av, Collindale, London NW9.
  • S. typhimurium NCTC 12023 ATCC 14028
  • S. enteritidis NCTC12694 ATCC13076
  • the present inventors also provide a plurality of previously uncharacterised useful gene sequences .
  • they provide sopA, pipD, orfX, pipC, pipB, pipA sopD and sipA .
  • the present invention also relates to nucleic acid, polypeptides, oligonucleotide probes and primers, diagnostic, prognostic and other materials and methods relating to these genes.
  • sequences for sopA, pipD, orfX, pipC, pipB and pipA are all newly provided by the present applicants (see figures 1 to 3 and 6). '
  • x gene' or 'allele' includes normal alleles of the genes disclosed herein (eg sopA, pipD etc) and also alleles which although carrying one or more variations retain the function of the gene and polypeptide sequences disclosed herein.
  • 'nucleic acid' includes a nucleic acid molecule which has a nucleotide sequence encoding a polypeptide which includes an amino acid sequence of a polypeptide as shown in figure 3/figure 6.
  • the coding sequence may be as shown in figure 3/figure 6 or it may be a mutant, variant, derivative or allele of a sequence as shown.
  • the sequence may differ from that shown by a change which is one or more of addition, insertion, deletion and substitution of one or more nucleotides of a sequence shown. Changes to a nucleotide sequence may result in an amino acid change at the protein level, or not, as determined by the genetic code.
  • nucleic acid according to the present invention may include a sequence which although different from a sequence shown in figure 3/figure 6 nevertheless encodes a polypeptide with the same amino acid sequence as shown in figure 3/figure 6.
  • the encoded polypeptide may comprise an amino acid sequence which differs by one or more amino acid residues from an amino acid polypeptide sequence as shown in figure 3/figure 6.
  • Nucleic acid encoding a polypeptide which is an amino acid sequence mutant, variant, derivative or allele of a polypeptide sequence as shown in figure 3/figure 6 is further provided by the present invention. Such polypeptides are discussed below.
  • Nucleic acid encoding such a polypeptide may show greater than about 20% homology with a coding sequence as shown in figure 3/figure 6, greater than about 30% homology, greater than about 40% homology, greater than about 50% homology, greater than about 60% homology, greater than about 70% homology, greater than about 80% homology, greater than about 90% or greater than about 95% homology.
  • Homologous sequences of requisite identity may be obtained as explained above.
  • nucleic acid molecules representing part or all of the sopA, pipD, pipC, orfX, pipB or pipA gene as set out in figure 3/figure 6 or alleles thereof. Also provided are nucleic acid molecules which have a nucleotide sequence encoding a sopA, pipD, pipC, orfX, pipB or pipA amino acid sequence set out in figure 3/figure 6.
  • nucleic acid molecules which have a nucleotide sequence encoding a polypeptide which is a mutant, variant, derivative or allele of a sopA, pipD, pipC, orfX, pipB or pipA polypeptide including the amino acid sequence set out in figure 3/figure 6.
  • nucleic acid molecules which have a nucleotide sequence encoding a fragment or active portion of a sopA, pipD, pipC, orfX, pipB or pipA polypeptide amino acid sequence set out in figure 3/figure 6.
  • a nucleic acid molecule as provided may comprise a nucleotide sequence functioning as a promoter region.
  • nucleic acid according to the present invention maybe provided as an isolate, in isolated and/or purified form, or free or substantially free of material with which it is naturally associated, such as free or substantially free of nucleic acid normally flanking the gene except possibly one or more regulatory sequence (s) for expression.
  • Nucleic acid may be wholly or partially synthetic and may include genomic DNA, cDNA or RNA. Where nucleic acid according to the invention includes RNA, reference to the sequence shown should be construed as reference to the RNA equivalent, with U substituted for T.
  • Nucleic acid molecules as provided may comprise a label .
  • a nucleic acid molecule as provided may be for use in a method of medical treatment or diagnosis.
  • Nucleic acid sequences as disclosed herein can be readily prepared by the skilled person using the information and references contained herein and techniques known in the art (for example, see Sambrook, Fritsch and Maniatis, "Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989, and Ausubel et al, Short Protocols in Molecular Biology, John Wiley and Sons, 1992) . These techniques include (i) the use of the polymerase chain reaction (PCR) to amplify samples of such nucleic acid, e.g. from suitable samples comprising Salmonella, Shigella or E. coli , (ii) chemical synthesis, or (iii) preparing cDNA sequences. Modifications to the sequences can be made, e.g. using site directed mutagenesis, to lead to the expression of modified polypeptide or to take account of codon preference in the host cells used to express the nucleic acid.
  • PCR polymerase chain reaction
  • the sequences can be incorporated in a vector having control sequences operably linked to control its expression.
  • the vectors may include other sequences such as promoters or enhancers to drive the expression of the inserted nucleic acid, nucleic acid sequences so that the polypeptide is produced as a fusion and/or nucleic acid encoding secretion signals so that the polypeptide produced in the host cell is secreted from the cell.
  • Polypeptide can then be obtained by transforming the vectors into host cells in which the vector is functional, culturing the host cells so that the polypeptide is produced and recovering the polypeptide from the host cells or the surrounding medium.
  • Prokaryotic and eukaryotic cells are used for this purpose in the art, including strains of E. coli, yeast, and eukaryotic cells such as COS or CHO cells.
  • the choice of host cell can be used to control the properties of the polypeptide expressed in those cells, e.g. controlling where the polypeptide is deposited in the host cells or affecting properties such as its glycosylation.
  • replicable vectors comprising a nucleic acid as hereby provided operably linked to control sequences to direct its expression; host cells transformed with such a vector; methods of producing a sopA, pipD, pipC, orfX, pipB or pipA polypeptide comprising culturing such a host cell so that polypeptide is produced - the method may comprise the further step of recovering the polypeptide produced.
  • PCR techniques for the amplification of nucleic acid are described in US Patent No. 4,683,195. In general, such techniques require that sequence information from the ends of the target sequence is known to allow suitable forward and reverse oligonucleotide primers to be designed to be identical or similar to the polynucleotide sequence that is the target for the amplification.
  • PCR comprises steps of denaturation of template nucleic acid (if double-stranded) , annealing of primer to target, and polymerisation.
  • the nucleic acid probed or used as template in the amplification reaction may be genomic DNA, cDNA or RNA.
  • PCR can be used to amplify specific sequences from genomic DNA, specific RNA sequences and cDNA transcribed from mRNA, bacteriophage or plasmid sequences.
  • the nucleic acid sequences provided herein see for example figure 3 and figure 6 readily allow the skilled person to design PCR primers.
  • References for the general use of PCR techniques include Mullis et al , Cold Spring Harbor Symp. Quant. Biol., 51:263, (1987), Ehrlich (ed) , PCR technology, Stockton Press, NY, 1989, Ehrlich et al, Science, 252:1643-1650, (1991), "PCR protocols; A Guide to Methods and Applications", Eds. Innis et al , Academic Press, New York, (1990) .
  • antisense oligonucleotide sequences based on the nucleic acid sequences described herein.
  • Antisense oligonucleotides may be designed to hybridise to the complementary sequence of nucleic acid, pre-mRNA or mature mRNA, interfering with the production of polypeptide encoded by a given DNA sequence (e.g. either native polypeptide or a mutant form thereof) , so that its expression is reduced or prevented altogether!
  • a given DNA sequence e.g. either native polypeptide or a mutant form thereof
  • the construction of antisense sequences and their use is described in Peyman and Ulman, Chemical Reviews, 90:543- 584, (1990), Crooke, Ann. Rev. Pharmacol. Toxicol . , 32:329-376, (1992), and Zamecnik and Stephenson, P.N.A.S, 75:280-284, (1974) .
  • nucleic acid sequences provided in figure 3 and figure 6 are useful for identifying nucleic acid of interest (and which may be according to the present invention) in a test sample.
  • the present invention provides a method of obtaining nucleic acid of interest, the method including hybridisation of a probe having a sequence shown in figure 3 or figure 6 or a complementary sequence thereto to target nucleic acid.
  • Hybridisation is generally followed by identification of successful hybridisation and isolation of nucleic acid which has hybridised to the probe, which may involve one or more steps of PCR.
  • nucleic acid according to the present invention is obtainable using one or more oligonucleotide probes or primers designed to hybridise with one or more fragments of the nucleic acid sequence shown in figure 3 or figure 6, particularly fragments of relatively rare sequence, based on codon usage or statistical analysis.
  • a primer designed to hybridise with a fragment of the nucleic acid sequence shown may be used in conjunction with one or more oligonucleotides designed to hybridise to a sequence in a cloning vector within which target nucleic acid has been cloned, or in so-called "RACE" (rapid amplification of cDNA ends) in which cDNA's in a library are ligated to an oligonucleotide linker and PCR is performed using a primer which hybridises with the sequence shown in figure 3 or figure 6 and a primer which hybridises to the oligonucleotide linker.
  • RACE rapid amplification of cDNA ends
  • the conditions of the hybridisation can be controlled to minimise non-specific binding, and preferably stringent to moderately stringent hybridisation conditions are preferred.
  • the skilled person is readily able to design such probes, label them and devise suitable conditions for the hybridisation reactions, assisted by textbooks such as Sambrook et al (1989) and Ausubel et al (1992) .
  • Binding of a probe to target nucleic acid may be measured using any of a variety of techniques at the disposal of those skilled in the art.
  • probes may be radioactively, fluorescently or enzymatically labelled.
  • Other methods not employing labelling of probe include examination of restriction fragment length polymorphisms, amplification using PCR, RNAase cleavage and allele specific oligonucleotide probing .
  • Probing may employ the standard Southern blotting technique. For instance nucleic acid material may be extracted from cells and digested with different restriction enzymes. Restriction fragments may then be separated by electrophoresis on an agarose gel, before denaturation and transfer to a nitrocellulose filter. Labelled probe may be hybridised to the DNA fragments on the filter and binding determined.
  • Preliminary experiments may be performed by hybridising under low stringency conditions various probes to Southern blots of DNA digested with restriction enzymes. Suitable conditions would be achieved when a large number of hybridising fragments were obtained while the background hybridisation was low.
  • oligonucleotide probes or primers may be designed, taking into account the degeneracy of the genetic code, and, where appropriate, codon usage of the organism from the candidate nucleic acid is derived.
  • An oligonucleotide for use in nucleic acid amplification may have about 10 or fewer codons (e.g. 6, 7 or 8), i.e. be about 30 or fewer nucleotides in length (e.g. 18, 21 or 24) .
  • Generally specific primers are upwards of 14 nucleotides in length, but not more than 18-20. Those skilled in the art are well versed in the design of primers for use processes such as PCR.
  • a further aspect of the present invention provides an oligonucleotide or polynucleotide fragment of a nucleotide sequence shown in figure 3 or figure 6 or a complementary sequence, in particular for use in a method of obtaining and/or screening nucleic acid.
  • the sequences referred to above may be modified by addition, substitution, insertion or deletion of one or more nucleotides, but preferably without abolition of ability to hybridise selectively with nucleic acid with a sequence shown in figure 3 or figure 6, that is wherein the degree of homology of the oligonucleotide or polynucleotide with one of the sequences given is sufficiently high.
  • nucleic acid probe having all or a portion of a sequence shown in figure 3 or figure 6 or a complementary sequence thereof, the method comprising contacting the probe and the test sample under hybridising conditions and observing whether hybridisation takes place.
  • the probe may be used to identify a sopA, pipD, pipC, orfX, pipB or pipA nucleic acid sequence or a mutant allele thereof.
  • Such probes may be used to identify the presence in the test sample of Salmonella, and other enteric bacteria (eg Shigella and E. coli) .
  • Oligonucleotides according to the present invention that are fragments of any of the sequences shown in figure 3 or figure 6 are at least about 10 nucleotides in length, more preferably at least about 15 nucleotides in length, more preferably at least about 20 nucleotides in length. Such fragments themselves individually represent aspects of the present invention. Fragments and other oligonucleotides may be used as primers or probes as discussed but may also be generated (e.g. by PCR) in methods concerned with determining the presence in a test sample of a sequence indicative of Salmonella, and other enteric bacteria (eg Shigella and E. coli) .
  • nucleic acid in diagnostic and/or prognostic contexts, for instance in determining infection with Salmonella, and other enteric bacteria (eg Shigella and E. coli ) and other methods concerned with determining the presence of sequences indicative of such infection are discussed below.
  • Nucleic acid according to the present invention such as a full-length coding sequence or oligonucleotide probe or primer, may be provided as part of a kit, e.g. in a suitable container such as a vial in which the contents are protected from the external environment .
  • the kit may include instructions for use of the nucleic acid, e.g. in PCR and/or a method for determining the presence of nucleic acid of interest in a test sample.
  • a kit wherein the nucleic acid is intended for use in PCR may include one or more other reagents required for the reaction, such as polymerase, nucleosides, buffer solution etc.
  • the nucleic acid may be labelled.
  • a kit for use in determining the presence or absence of nucleic acid of interest may include one or more articles and/or reagents for performance of the method, such as means for providing the test sample itself, e.g. a swab or a syringe (such components generally being sterile) .
  • a convenient way of producing a polypeptide as disclosed herein is to express nucleic acid encoding it, by use of the nucleic acid in an expression system.
  • the use of expression system has reached an advanced degree of sophistication today.
  • the present invention also encompasses a method of making a polypeptide (as disclosed; see below) , the method including expression from nucleic acid (generally nucleic acid according to the invention) encoding the polypeptide. This may conveniently be achieved by growing a host cell in culture, containing such a vector, under appropriate conditions which cause or allow expression of the polypeptide. Polypeptides may also be expressed in in vitro systems, such as reticulocyte lysate.
  • Suitable host cells include bacteria, eukaryotic cells such as mammalian and yeast, and baculovirus systems.
  • Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells, COS cells and many others.
  • a common, preferred bacterial host is E. coli.
  • Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate.
  • Vectors may be plasmids, viral e.g. 'phage, or phagemid, as appropriate. For further details see, for example, Molecular Cloning: a Laboratory
  • nucleic acid of the invention may be integrated into the genome (e.g. chromosome) of a host cell. Integration may be promoted by inclusion of sequences which promote recombination with the genome, in accordance with standard techniques.
  • the nucleic acid may be on an extra-chromosomal vector within the cell.
  • a still further aspect provides a method which includes introducing the nucleic acid into a host cell.
  • the introduction which may (particularly for in vitro introduction) be generally referred to without limitation as "transformation", may employ any available technique.
  • suitable techniques may include calcium phosphate transfection, DEAE-Dextran, electroporation, liposome-mediated transfection and transduction using retrovirus or other virus, e.g. vaccinia or, for insect cells, baculovirus.
  • suitable techniques may include calcium chloride transformation, electroporation and transfection using bacteriophage.
  • direct injection of the nucleic acid could be employed.
  • Marker genes such as antibiotic resistance or sensitivity genes may be used in identifying clones containing nucleic acid of interest, as is well known in the art.
  • the introduction may be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells (which may include cells actually transformed although more likely the cells will be descendants of the transformed cells) under conditions for expression of the gene, so that the encoded polypeptide is produced. If the polypeptide is expressed coupled to an appropriate signal leader peptide it may be secreted from the cell into the culture medium.
  • a polypeptide may be isolated and/or purified from the host cell and/or culture medium, as the case may be, and subsequently used as desired, e.g. in the formulation of a composition which may include one or more additional components, such as a pharmaceutical composition which includes one or more pharmaceutically acceptable excipients, vehicles or carriers (e.g. see below) .
  • a host cell containing nucleic acid according to the present invention e.g. as a result of introduction of the nucleic acid into the cell or into an ancestor of the cell and/or genetic alteration of the sequence endogenous to the cell or ancestor (which introduction or alteration may take place in vivo or ex vivo) , may be comprised (e.g. in the soma) within an organism which is an animal.
  • host cells may be used as a nucleic acid factory to replicate the nucleic acid of interest in order to generate large amounts of it .
  • Multiple copies of nucleic acid of interest may be made within a cell when coupled to an amplifiable gene such as DHFR.
  • Host cells transformed with nucleic acid of interest, or which are descended from host cells into which nucleic acid was introduced, may be cultured under suitable conditions, e.g. in a fermenter, taken from the culture and subjected to processing to purify the nucleic acid. Following purification, the nucleic acid or one or more fragments thereof may be used as desired, for instance in a diagnostic or prognostic assay as discussed elsewhere herein.
  • a further aspect of the present invention provides a polypeptide which has an amino acid sequence shown in figure 3 or figure 6, which may be in isolated and/or purified form, free or substantially free of material with which it is naturally associated.
  • the present invention also provides a substance which is a sopA, pipD, pipC, orfX, pipB or pipA polypeptide encoded by a nucleic acid molecule as stated above. Also provided is a substance which is a sopA, pipD, pipC, orfX, pipB or pipA polypeptide including the amino acid sequence set out in figure 3 or figure 6.
  • a polypeptide which is a variant, allele, derivative or mutant may have an amino acid sequence which differs from that given in figure 3 or figure 6 by one or more of addition, substitution, deletion and insertion of one or more amino acids.
  • Preferred such polypeptides have a function broadly equivalent to the native polypeptides, that is to say have one or more of the following properties: immunological cross-reactivity with an antibody reactive with a polypeptide for which the sequence is given in figure 3 or figure 6; sharing an epitope with a polypeptide for which the amino acid sequence is shown in figure 3 or figure 6 (as determined for example by immunological cross-reactivity between the two polypeptides) .
  • a polypeptide which is an amino acid sequence variant, allele, derivative or mutant of an amino acid sequence shown in figure 3 or figure 6 may comprise an amino acid sequence which shares greater than about 20% sequence identity, greater than about 30%, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, greater than about 90% or greater than about 95%.
  • the sequence may share greater than about 50% similarity, greater than about 60% greater than about 70% similarity, greater than about 80% similarity or greater than about 90% similarity with an amino acid sequence shown in figure 3 or figure 6.
  • Particular amino acid sequence variants may differ from those shown in figure 3 or figure 6 by insertion, addition, substitution or deletion of 1 amino acid, 2, 3, 4, 5-10, 10-20 20-30, 30-50, 50-100, 100-150, or more than 150 amino acids.
  • the present invention also includes active portions, fragments, derivatives and functional mimetics of the polypeptides provided herein.
  • An "active portion" of a sopA, pipD, orfX, pipC, pipB and pipA polypeptide means a peptide which is less than the full length polypeptide, but which retains its essential biological activity.
  • a “fragment” of the polypeptide means a stretch of amino acid residues of at least about five to seven contiguous amino acids, often at least about seven to nine contiguous amino acids, typically at least about nine to 13 contiguous amino acids and, most preferably, at least about 20 to 30 or more contiguous amino acids. Fragments may comprise the antigenic determinants or epitopes characteristic of the wild-type full length polypeptide which are useful for raising antibodies.
  • a “derivative" of the polypeptide or a fragment thereof means a polypeptide modified by varying the amino acid sequence of the protein, e.g. by manipulation of the nucleic acid encoding the protein or by altering the protein itself. Such derivatives of the natural amino acid sequence may involve insertion, addition, deletion or substitution of one or more amino acids, without fundamentally altering the essential activity of the wild type polypeptide.
  • “Functional mimetic” means a substance which may not contain an active portion of the native amino acid sequence, and probably is not a peptide at all, but which retains the essential biological activity of natural polypeptide. The design and screening of candidate mimetics is described in detail below.
  • a polypeptide according to the present invention may be isolated and/or purified (e.g. using an antibody) for instance after production by expression from encoding nucleic acid. Polypeptides according to the present invention may also be generated wholly or partly by chemical synthesis using the sequence information provided. The isolated and/or purified polypeptide may be used in formulation of a composition, which may include at least one additional component, for example a vaccine composition including a pharmaceutically acceptable excipient, vehicle or carrier. A composition including a polypeptide according to the invention may be used in prophylactic and/or therapeutic treatment as discussed herein.
  • a polypeptide, peptide fragment, allele, mutant or variant according to the present invention may be used as an immunogen or otherwise in obtaining antibodies that have the property of specifically binding to the polypeptides, fragments, alleles, mutants, variants or active portions thereof.
  • Antibodies are useful in purification and other manipulation of polypeptides and peptides, diagnostic screening and therapeutic contexts. This is discussed further herein.
  • a polypeptide according to the present invention may be used in screening for molecules which affect or modulate its activity or function. Such molecules may be useful in a therapeutic context.
  • Monoclonal antibodies can be subjected to the techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs) , of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP-A-184187, GB-A-2188638 or EP-A-239400.
  • a hybridoma producing a monoclonal antibody may be subject to genetic mutation or other changes, which may or may not alter the binding specificity of antibodies produced.
  • a further aspect of the present invention provides an antibody able to bind specifically to a polypeptide as hereby provided eg a polypeptide whose sequence is given in figure 3.
  • a polypeptide as hereby provided eg a polypeptide whose sequence is given in figure 3.
  • Such an antibody may be specific in the sense of being able to distinguish between the polypeptide it is able to bind and other polypeptides for which it has no or substantially no binding affinity (e.g. a binding affinity of about lOOOx worse) .
  • Specific antibodies bind an epitope on the molecule which is either not present or is not accessible on other molecules.
  • Antibodies according to the present invention may be specific for the wild-type polypeptide.
  • Antibodies according to the invention may be specific for a particular mutant, variant, allele or derivative polypeptide as between that molecule and the wild-type polypeptide, so as to be useful in diagnostic and prognostic methods. Antibodies are also useful in purifying the polypeptide or polypeptides to which they bind, e.g. following production by recombinant expression from encoding nucleic acid.
  • antibodies capable of specifically binding to a sopA, pipD, pipC, orfX, pipB or pipA polypeptide as above.
  • Antibodies may be labelled. They may be used to determine the presence, amount or location in a sample of the polypeptides above or Salmonella, and other enteric bacteria (eg Shigella and E. coli) .
  • Preferred antibodies according to the invention are isolated, in the sense of being free from contaminants such as antibodies able to bind other non-related polypeptides and/or free of serum components. Monoclonal antibodies are preferred for some purposes, though polyclonal antibodies are within the scope of the present invention.
  • Antibodies may be obtained using techniques which are standard in the art. Methods of producing antibodies include immunising a mammal (e.g. mouse, rat, rabbit, horse, goat, sheep or monkey) with the protein or a fragment thereof. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and screened, preferably using binding of antibody to antigen of interest. For instance,
  • an antibody specific for a protein may be obtained from a recombinantly produced library of expressed immunoglobulin variable domains, e.g. using lambda bacteriophage or filamentous bacteriophage which display functional immunoglobulin binding domains on their surfaces; for instance see WO92/01047.
  • the library may be naive, that is constructed from sequences obtained from an organism which has not been immunised with any of the proteins (or fragments) , or may be one constructed using sequences obtained from an organism which has been exposed to the antigen of interest.
  • Antibodies according to the present invention may be modified in a number of ways. Indeed the term “antibody” should be construed as covering any binding substance having a binding domain with the required specificity. Thus the invention covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, including synthetic molecules and molecules whose shape mimics that of an antibody enabling it to bind an antigen or epitope.
  • Example antibody fragments capable of binding an antigen or other binding partner are the Fab fragment consisting of the VL, VH, Cl and CHI domains; the Fd fragment consisting of the VH and CHI domains; the Fv fragment consisting of the VL and VH domains of a single arm of an antibody; the dAb fragment which consists of a VH domain; isolated CDR regions and F(ab')2 fragments, a bivalent fragment including two Fab fragments linked by a disulphide bridge at the hinge region. Single chain Fv fragments are also included.
  • a hybridoma producing a monoclonal antibody according to the present invention may be subject to genetic mutation or other changes. It will further be understood by those skilled in the art that a monoclonal antibody can be subjected to the techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs) , of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP-A-184187, GB-A-2188638 or EP-A-0239400.
  • CDRs complementarity determining regions
  • Hybridomas capable of producing antibody with desired binding characteristics are within the scope of the present invention, as are host cells, eukaryotic or prokaryotic, containing nucleic acid encoding antibodies (including antibody fragments) and capable of ' their expression.
  • the invention also provides methods of production of the antibodies including growing a cell capable of producing the antibody under conditions in which the antibody is produced, and preferably secreted.
  • the reactivities of antibodies on a sample may be determined by any appropriate means . Tagging with individual reporter molecules is one possibility.
  • the reporter molecules may directly or indirectly generate detectable, and preferably measurable, signals.
  • the linkage of reporter molecules may be directly or indirectly, covalently, e.g. via a peptide bond or non- covalently. Linkage via a peptide bond may be as a result of recombinant expression of a gene fusion encoding antibody and reporter molecule.
  • Suitable fluorochromes include fluorescein, rhodamine, phycoerythrin and Texas Red.
  • Suitable chromogenic dyes include diaminobenzidine .
  • Other reporters include macromolecular colloidal particles or particulate material such as latex beads that are coloured, magnetic or paramagnetic, and biologically or chemically active agents that can directly or indirectly cause detectable signals to be visually observed, electronically detected or otherwise recorded.
  • These molecules may be enzymes which catalyse reactions that develop or change colours or cause changes in electrical properties, for example. They may be molecularly excitable, such that electronic transitions between energy states result in characteristic spectral absorptions or emissions. They may include chemical entities used in conjunction with biosensors. Biotin/avidin or biotin/streptavidin and alkaline phosphatase detection systems may be employed.
  • the mode of determining binding is not a feature of the present invention and those skilled in the art are able to choose a suitable mode according to their preference and general knowledge.
  • Antibodies according to the present invention may be used in screening for the presence of a polypeptide according to the present invention, for example in a test sample containing cells or cell lysate as discussed, and may be used in purifying and/or isolating a polypeptide according to the present invention, for instance following production of the polypeptide by expression from encoding nucleic acid therefor.
  • Antibodies may modulate the activity of the polypeptide to which they bind and so, if that polypeptide has a deleterious effect in an individual, may be useful in a therapeutic context (which may include prophylaxis) .
  • An antibody may be provided in a kit, which may include instructions for use of the antibody, e.g. in determining the presence of a particular substance in a test sample.
  • One or more other reagents may be included, such as labelling molecules, buffer solutions, elutants and so on. Reagents may be provided within containers which protect them from the external environment, such as a sealed vial .
  • a number of methods are known in the art for analysing biological samples from individuals to determine whether the individual carry an undesirable bacterial species such as Salmonella, and other enteric bacteria (eg Shigella and E. coli ) .
  • the methods divide into those screening for the presence of nucleic acid sequences characteristic of the virus and those that rely on detecting the presence or absence of polypeptide or characteristic antibody thereto .
  • the methods make use of biological samples from individuals that are suspected of contain the nucleic acid sequences or polypeptide. Examples of biological samples include blood, plasma, serum, tissue samples.
  • nucleic acid in the sample will initially be amplified, e.g. using PCR, to increase the amount of the analyte as compared to other sequences present in the sample. This allows the target sequences to be detected with a high degree of sensitivity if they are present in the sample. This initial step may be avoided by using highly sensitive array techniques that are becoming increasingly important in the art.
  • a sample may be tested for the presence of a binding partner for a specific binding member such as an antibody (or mixture of antibodies) , specific for one or more particular variants of a polypeptide shown in figure 3 or figure 6.
  • a binding partner for a specific binding member such as an antibody (or mixture of antibodies) , specific for one or more particular variants of a polypeptide shown in figure 3 or figure 6.
  • a sample may be tested for the presence of a binding partner for a specific binding member such as an antibody (or mixture of antibodies) , specific for a polypeptide shown in figure 3 or figure 6.
  • a binding partner for a specific binding member such as an antibody (or mixture of antibodies) , specific for a polypeptide shown in figure 3 or figure 6.
  • the sample may be tested by being contacted with a specific binding member such as an antibody under appropriate conditions for specific binding, before binding is determined, for instance using a reporter system.
  • a specific binding member such as an antibody under appropriate conditions for specific binding
  • different reporting labels may be employed for each antibody so that binding of each can be determined.
  • a specific binding member such as an antibody may be used to isolate and/or purify its binding partner polypeptide from a test sample, to allow for sequence and/or biochemical analysis of the polypeptide to determine whether it has the sequence and/or properties of a polypeptide whose sequence is shown in figure 3 or figure 6, or if it is a mutant or variant form thereof.
  • Amino acid sequence is routine in the art using automated sequencing machines.
  • the present invention provides a kit comprising a support or diagnostic chip having immobilised thereon one or more binding agents capable of specifically binding nucleic acid as provided herein optionally in combination with other reagents (such as labelled developing reagents) needed to carrying out an assay.
  • the mutant bacteria, polypeptides, antibodies, peptides and nucleic acid of the invention can be formulated in pharmaceutical compositions for the prevention or treatment of infection by Salmonella, and other enteric bacteria (eg Shigella and E. coli ) .
  • enteric bacteria eg Shigella and E. coli
  • the gene products wild type or genetically modified/detoxified
  • an attenuated carrier strain e.g. Salmonella, and other enteric bacteria
  • pharmaceutical compositions may comprise, in addition to one of the above substances, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient .
  • the precise nature of the carrier or other material may depend on the route of administration, e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.
  • compositions for oral administration may be in tablet, capsule, powder or liquid form.
  • a tablet may include a solid carrier such as gelatin or an adjuvant.
  • Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol , propylene glycol or polyethylene glycol may be included.
  • the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
  • a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
  • isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection.
  • Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.
  • administration is preferably in a "prophylactically effective amount” or a "therapeutically effective amount” (as the case may be, although prophylaxis may be considered therapy) , this being sufficient to show benefit to the individual .
  • a prophylaxis may be considered therapy
  • the actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g.
  • a polypeptide according to the present invention may be used in screening for molecules which affect or modulate its activity or function. Such molecules may be useful in a therapeutic (possibly including prophylactic) context .
  • a method of screening for a substance which modulates activity of a polypeptide may include contacting one or more test substances with the polypeptide in a suitable reaction medium, testing the activity of the treated polypeptide and comparing that activity with the activity of the polypeptide in comparable reaction medium untreated with the test substance or substances. A difference in activity between the treated and untreated polypeptides is indicative of a modulating effect of the relevant test substance or substances.
  • Combinatorial library technology provides an efficient way of testing a potentially vast number of different substances for ability to modulate activity of a polypeptide.
  • Such libraries and their use are known in the art.
  • the use of peptide libraries is preferred.
  • test substances Prior to or as well as being screened for modulation of activity, test substances may be screened for ability to interact with the polypeptide, e.g. in a yeast two-hybrid system (which requires that both the polypeptide and the test substance can be expressed in yeast from encoding nucleic acid) . This may be used as a coarse screen prior to testing a substance for actual ability to modulate activity of the polypeptide.
  • the substance may be investigated further. Furthermore, it may be manufactured and/or used in preparation, i.e. manufacture or formulation, of a composition such as a medicament, pharmaceutical composition or drug. These may be administered to individuals.
  • the present invention extends in various aspects not only to a substance identified using a nucleic acid molecule as a modulator of polypeptide activity, in accordance with what is disclosed herein, but also a pharmaceutical composition, medicament, drug or other composition comprising such a substance, a method comprising administration of such a composition to a patient, e.g. for treatment (which may include preventative treatment) of infection by Salmonella, and other enteric bacteria (eg Shigella and E. coli) , use of such a substance in manufacture of a composition for administration and a method of making a pharmaceutical composition comprising admixing such a substance with a pharmaceutically acceptable excipient, vehicle or carrier, and optionally other ingredients.
  • a pharmaceutical composition, medicament, drug or other composition comprising such a substance, a method comprising administration of such a composition to a patient, e.g. for treatment (which may include preventative treatment) of infection by Salmonella, and other enteric bacteria (eg Shigella and E. coli) , use of such
  • a substance identified using as a modulator of polypeptide function may be peptide or non-peptide in nature.
  • Non-peptide "small molecules" are often preferred for many in vivo pharmaceutical uses. Accordingly, a mimetic or mimic of the substance (particularly if a peptide) may be designed for pharmaceutical use.
  • the designing of mimetics to a known pharmaceutically active compound is a known approach to the development of pharmaceuticals based on a "lead" compound. This might be desirable where the active compound is difficult or expensive to synthesise or where it is unsuitable for a particular method of administration, e.g. peptides are unsuitable active agents for oral compositions as they tend to be quickly degraded by proteases in the alimentary canal.
  • Mimetic design, synthesis and testing is generally used to avoid randomly screening large number of molecules for a target property.
  • the pharmacophore Once the pharmacophore has been found, its structure is modelled to according its physical properties, eg stereochemistry, bonding, size and/or charge, using data from a range of sources, eg spectroscopic techniques, X- ray diffraction data and NMR. Computational analysis, similarity mapping (which models the charge and/or volume of a pharmacophore, rather than the bonding between atoms) and other techniques can be used in this modelling process .
  • a range of sources eg spectroscopic techniques, X- ray diffraction data and NMR.
  • Computational analysis, similarity mapping which models the charge and/or volume of a pharmacophore, rather than the bonding between atoms
  • other techniques can be used in this modelling process .
  • the three-dimensional structure of the ligand and its binding partner are modelled. This can be especially useful where the ligand and/or binding partner change conformation on binding, allowing the model to take account of this in the design of the mimetic.
  • a template molecule is then selected onto which chemical groups which mimic the pharmacophore can be grafted.
  • the template molecule and the chemical groups grafted on to it can conveniently be selected so that the mimetic is easy to synthesise, is likely to be pharmacologically acceptable, and does not degrade in vivo, while retaining the biological activity of the lead compound.
  • the mimetic is peptide based
  • further stability can be achieved by cyclising the peptide, increasing its rigidity.
  • the mimetic or mimetics found by this approach can then be screened to see whether they have the target property, or to what extent they exhibit it. Further optimisation or modification can then be carried out to arrive at one or more final mimetics for in vivo or clinical testing.
  • nucleotides and polypeptides as provided herein have several clear applications inter alia :
  • PCR primers can be designed for the detection of Salmonellas or Salmonellas and Shigellas .
  • the gene products themselves may be used as sub-unit vaccines for the control of Salmonellosis .
  • Polyclonal antibodies against eg sopD have been obtained indicating the immunogenecity of the sopD polypeptide.
  • Antibodies eg anti-sopD may be utilised for immunodiagnostics or treatment of Salmonellosis .
  • the Sop proteins were isolated as described earlier (Wood et al . , 1996) . The proteins were separated by SDS-PAGE and stained with Coomassie blue. SopD band was excised from the gel, and the acrylamide was finely dispersed in a Griffin's tube in a minimal volume of sterile PBSa . This suspension was then used to inoculate rabbits.
  • FIG. 1 Schematic representation of physical and genetic map of SPI-5.
  • Figure 2 Sequence analysis of junctions between S. dublin DNA homologous and non-homologous to E. coli K-12 DNA.
  • Figure 3 Nucleotide sequence of SPI-5 with putative amino acid sequences of encoded proteins.
  • Figure 4 Effect of different mutations within SPI-5 on the ability of S. dublin to induce fluid secretion and PMN influx 12 h after infection of bovine ligated ileal loops.
  • the secretory response is defined as the volume of fluid within a loop per length of loop and the PMN influx is defined as the radioactive count of PMNs within test loops per radioactive count of PMNs within the negative control loops.
  • Each bar is derived from the mean from four loops and is presented with the standard error of the mean.
  • the decreased enteropathogenicity in bovine ileal loops correlates with reduced oral virulence of mutants for calves.
  • Lane 5 PCR analyses of different bacterial strains using SPI -5-specific primers.
  • Lane 0 contain DNA markers, the other lanes contain PCR products amplified using the following bacterial suspensions as templates: 1. S. anatum 997; 2. S . choleraesuis A57; 3. S . dublin 2229; 4. S. enteri tidis 149; 5. S . gallinarum 289/91; 6. S.pulloru 449/87; 7. S . typhimurium C5 ; 8. Shigella sonnei PB1; 9. E. coli H310 (EPEC) ; 10. Yersinia pseudotuberculosis YPIIl/pIB102.
  • the primers used were:
  • PA1 (5 ' -caggcgaagcctttgaaac-3 ' ) and PA2 (5'- ctgggaggtgaaggatgcc-3 ' ) , pipA-specific .
  • PB1 (5 ' -cgcaataaagatctcgatctacagacggt-3 ' ) and PB2 (5'- tgccgcttttcgaattccaggcgggt-3 ' ) , sopB-specific .
  • FIG. 7 Effect of mutation in sopA on the ability of S . dublin to induce fluid secretion and inflammatory response (PMN influx) 12h after infection of bovine ligated ileal loops.
  • the secretory response and PMN influx are as defined above in relation to Figure 4.
  • Bacterial strains and growth condi tions The bacterial strains used in this study are listed in Table 1. Strains were grown in LB broth or on LB agar with the addition of appropriate antibiotics when necessary.
  • pMW60 was used as a template for DNA sequencing using a Sequenase kit, version 2 (USB Corp.) according to the manufacturer' s instructions .
  • PRA2 (5 ' -aagtaatatcacccgtgaataa-3 ' ) .
  • PRB1 (5 ' -cggtcttactcgagcggggctttgct-3 ' )
  • PRB2 (5 ' -gggttaacaaccctttaaaagg-3 ' ) .
  • Probe C PRC1 (5 ' -taacgcgattgctctattacac-3 ' )
  • PRC2 5 ' -tattctttgccgcgatcctttat-3 ' ) .
  • PRD1 (5 ' -ttcctgctcctctggttac-3 ' )
  • PRD2 (5 ' -ccggacggtcataatgaga-3 ' ) .
  • S . dublin PA1 (insertion of a suicide vector into pipA) : An internal DNA fragment of pipA amplified by PCR using S . dublin 2229 chromosomal DNA as a template and two oligonucleotide primers, PIPA1 (5'- cacctacagatctatacctcaaagcggagt-3 ' ) , and PIPA2 (5 ' - cagcgctgctcgagatcatgtagttcttt-3 ' ) . This DNA fragment was then cloned into the suicide plasmid vector pDM4 (Milton et al . , 1996). The resulting plasmid pPAl was conjugated from E.
  • S coli S17.1 into S. dublin 2229 and Cm R transconjugants were obtained.
  • the insertion of the suicide vector by a single recombination event into the chromosome of S. dublin 2229 resulted in a pipA mutant, which was denoted S . dublin PA1.
  • S . dublin PD1 insertion of suicide vector into pipD
  • S . dublin KIN insertion of suicide vector into copS
  • PIPD1 (5'- ccttcattctcgagcgcaacgagat-3 ' ) and PIPD2 (5'- caggatcacggatccaatggcgtcttccgt-3 ' ) primers were used to amplify an internal fragment of pipD; COPS1 (5'- cgcagaatggttaagttatctagaacgctg-3 ' ) and COPS2 (5 1 - ggcattcgtcagcaggctcgagagcactctttg-3 ' ) primers were used to amplify an internal fragment of copS.
  • SPIPB1 (5 ' -taaaatatttctcgaggatgtcaacgggt-3 ' )
  • SPIPB2 (5 ' -AGTCTGAGCCGtttgtttcacggaaatct-3 ' )
  • SPIPB3 (5 ' -CCGTGAAACAAAcggctcagacttaactgac-3 ' )
  • SPIPB4 5 ' -cacatacagatctcgctatgattcagac-3 ' ) were designed to generate a fusion DNA fragment covering the 5' and 3' area of pipB and carrying a 156 bp long deletion of the internal part of the gene.
  • Two DNA fragments were amplified by PCR using S . dublin 2229 chromosomal DNA as a template and SPIPB1 and SPIPB2 and
  • SPIPB3 and SPIPB4 respectively. These DNA fragments were then used as a template as a template in a PCR reaction with SPIPB1 and SPIPB4.
  • the resulting DNA fragment was cloned into the suicide plasmid vector pDM4 (Milton et al., 1996) to yield pDPIPBl.
  • pDPIPBl was conjugated from E. coli S17.1 into S . dublin 2229 and Cm r transconjugants were obtained.
  • the suicide plasmid was then excised by a second recombination event as described in (Milton et al., 1996).
  • the Cm sensitive recombinants were obtained and screened by PCR for a mutated allele.
  • S. dublin PB2 Several clones carrying the deletion were identified. One of these was designated S . dublin PB2 and used in further experiments.
  • S.dublin SD1 insertion of a suicide vector into sopD
  • two oligonucleotide primers SD1 5'TTA TGC CAG TCG ACT TAA GCT TCG GTA AT-3 '
  • SD2 5'-TGA TAG TAA ACA GAT CTT GAT GAG C-3 '
  • SD1 5'TTA TGC CAG TCG ACT TAA GCT TCG GTA AT-3 '
  • SD2 5'-TGA TAG TAA ACA GAT CTT GAT GAG C-3 '
  • the corresponding DNA fragment was amplified by PCR using S . dublin 2229 chromosomal DNA as template. This DNA fragment was used as a probe to screen a plasmid library of S. dublin chromosomal DNA. Two positive clones were identified, one of which was denoted pMW45 and chosen for sequencing and transcomplementation experiments.
  • the sopD mutants of S. dublin were constructed as follows. An internal DNA fragment of sopD was amplified by PCR with SD1 and SD2 using and was cloned into the suicide plasmid vector pDM4. The resulting plasmid was conjugated from E. coli S17.1 into S . dublin 2229 and Cml r transconjugants were obtained. One of these clones was denoted S. dublin SD1 and chosen for further experiments. The correct insertion of the suicide vector into the sopD gene was confirmed by the PCR.
  • the sopB/sopD mutant was constructed as follows.
  • the sopB mutant was constructed as described earlier (Galyov et al., 1997 Molecular Microbiology, 25, 903-12).
  • the sopD mutation was then transfected by P22 transduction into the sopB mutant strain S. dublin SB2 to yield S. dublin SB2SD1 mutant strain.
  • S.dublin Al SipA mutant was constructed as described previously (Wood et al., 1996 M.Microbiol. 22: 327-338).
  • the mutant forms of Salmonella were (as described above) prepared by use of the suicide plasmid technique. This technique is widely used. Those working in the field would also be able to make mutant forms as disclosed herein by other techniques.
  • the mutations may comprise point mutations, insertions, deletions, substitutions at one or more positions in the nucleotide sequences.
  • Bovine ligated ileal loop assay for enteropathogenesis This assay has been described in detail elsewhere (Wallis et al . , 1995).
  • the bacterial strains were grown overnight at 25°C, with shaking.
  • the cultures were diluted approximately 1 in 3 in fresh LB medium and incubated at 37°C for 90 min with shaking.
  • the optical density was adjusted by adding LB broth to give approximately 9.0 log 10 cfu ml "1 .
  • Sterile LB broth was used as the negative control.
  • Ligated ileal loops were constructed in the mid-ileum of 28-day-old, male, Friesian calves.
  • the bacterial culture (1 ml) was injected into loops of 6 cm in length.
  • Approximately 50 ml of blood were removed from the calf and the PMNs were isolated, labelled with llx In and reinjected into the calf.
  • Twelve hours after inoculation of the loops the secretory response (volume of fluid within a loop/length of a loop) was recorded.
  • the y- irradiation from each loop and its contents were measured and used to calculate the PMN influx ratio (irradiation from test loop/irradiation from negative control loop) .
  • the inventors used PCR amplified DNA fragments corresponding to the regions upstream and downstream of sopB as probes to identify clones from a S . dublin chromosomal DNA library containing the extended DNA fragments corresponding to the areas upstream and downstream of sopB .
  • This analysis revealed no clones hybridising with the DNA probe derived upstream of sopB .
  • One clone hybridising with the probe derived downstream of sopB was identified and the plasmid from this clone was designated pMW61 (Fig. 1) .
  • DNA cloned into pMW61 included a gene identical to the fRHA ⁇ 1 ( serT) gene from E. coli (Fig.2) .
  • a strong homology between S. dublin sequence and the corresponding sequence from E. coli K-12 extended from the serT promoter area (end of the cloned fragment) included the serT gene, a short fragment downstream of serT and a part of an inverted repeat terminator structure downstream of the gene (Fig.2).
  • Salmonella specific DNA suggesting that the enteropathogenicity associated sopB gene is located on the Salmonella-specific DNA fragment absent from the E. coli K-12 chromosome and that the site of the insertion for this fragment is the inverted repeat sequence downstream of serT.
  • Salmonella-specific DNA fragment has features characteristic to "pathogenicity islands" (for a review see Groisman and Ochman, 1996) , and has now been denoted SPI-5 (previously denoted SPI-4 by the inventors; see earlier comment) .
  • the copS gene is located at 46 centisome of the E. coli chromosome.
  • Two oligonucleotide primers were designed based on the determined sequence, a corresponding DNA fragment was amplified by PCR and used as a probe to identify another chromosomal DNA fragment suitable for cloning DNA extending further upstream of sopB .
  • the inventors obtained a set of overlapping clones extending approximately 8 kb upstream of sopB (Fig.l). Further sequence analysis of the DNA fragment cloned into pMW58 and pMW57 revealed that the copS gene is followed by the copR and ORF genes (Fig.l) .
  • copS, copR and ORF genes are structurally similar to the corresponding genes from E. coli and the relative gene order and orientation is conserved in S . dublin and E. coli K-12.
  • SPI-5 of S. dublin appears to be flanked by the serT on one side and copS followed by copR and ORF genes on the other side (Fig.l) .
  • the pipA gene product does not appear to have significant homology to previously described proteins, whereas the other SPI-5 encoded gene products showed sequence similarity to gene products from other bacterial species (Fig.l) .
  • the inventors have previously shown that the sopB gene product is homologous to IpgD protein from Shigella (Allaoui et al . , 1993).
  • the predicted protein product pipC is similar to the IpgE proteins of Shigella (Allaoui et al . , 1993) .
  • the sopB and pipC are likely to form an operon, similar in organisation to the ipgD/ipgE operon from Shigella (Allaoui et al . , 1993) .
  • pipB encodes a putative membrane associated protein with two transmembrane helices.
  • the pipB gene product is structurally similar to the HglK protein from Anabaena and Synechocystis species (Black et al . , 1995), as well as to several other putative membrane proteins from Synechocystis .
  • the pipD gene product is a structural homolog to dipeptidases from two different Lactobacillus species.
  • the gene product of orfX is similar to a putative protein ECU82528 from E. coli
  • the G+C content of SPI-5 is 46%, compared to 44.6% for SPI-2 (Shea et al . , 1996), 47% for SPI-1, 39.8-49.3% for SPI-3 (Blanc-Potard and Groisman, 1997) , and 52-54% estimated for the entire Salmonella genome (ref) .
  • SPI-5 is conserved in Salmonellae
  • a 1-kb sopB-specific DNA fragment was amplified by PCR and used as a probe in Southern blot hybridisation analysis of genomic DNA from different Salmonella serovars and some other pathogenic bacteria.
  • DNA fragment hybridisation showed that SPI-5 is present in S. typhimurium, S . enteri tidis, S . cholerae-suis ,
  • the position of the SPI-5 was determined by screening a prophage library of the S. typhimurium genome by PCR using primers to the genes sopB, pipD, serT and the junction of copS/copR .
  • the PCR products of the expected sizes were obtained when a template corresponding to 17 to 21.5 centisomes on the chromosome was present (data not shown) .
  • the inventors have previously demonstrated that the SopB protein is involved in enteropathogenicity of Salmonella (Galyov et al . , 1997).
  • they constructed mutants in the pipA, pipB, pipD and copS genes and assessed corresponding mutant strains for growth in vitro, invasiveness of HeLa cells, and enteropathogenicity in bovine ileal ligated loops.
  • the wild-type S . dublin 2229 and a sopB mutant S. dublin SB2 were also included as controls in the experiments .
  • the growth characteristics of the SPI-5, sipA and sopD pip mutant strains in vitro were undistinguishable from that of the wild-type.
  • the copS mutant showed reduced viability on McCconkey plates (data not shown) . None of the mutations affected the ability of Salmonella to invade cultured HeLa cells (data not shown) .
  • the pipA, pipB, pipD, sopB, sopD and sipA mutations significantly reduced the enteropathogenicity of the corresponding mutant strains (Fig.4) .
  • the copS mutant was nearly as enteropathogenic as the wild-type strain (Fig.4) .
  • sopB, sopD double mutant was significantly less enteropathogenic than the single sopB or sipD mutants indicating a synergistic effect of these mutations.
  • SPI-5-specific sequence to detect Salmonella serovars and distinguish them from other enteric bacterial pathogens was assessed by PCR.
  • Primers PD1 and PD2 were derived from the pipD sequence, PB1 and PB2 - from sopB, and PA1 and PA2 - from pipA . Bacterial suspensions of individual strains were used as templates.
  • the PCR reactions profile consisted of denaturation at 94 °C for 5 min, followed by 25 cycles of 94°C for 30 sec, 50°C for 30 sec, and 72°C for 30 sec in a DNA thermal cycler.
  • the analysis of PCR products by agarose gel electrophoresis showed that SPI -5 -specific sequences of expected sizes were amplified when different Salmonella serotypes were used as template. No PCR products were detected when Yersinia pseudotuberculosis, Shigella sonnei , and enteropathogenic E. coli were used as templates (Fig.5A, B, and C) .
  • primers derived from SPI-5 are suitable for specific detection of Salmonella by PCR.
  • Al Two pairs of degenerate oligonucleotide primers.
  • Al (5- gaYWSNccNatHgaRttYgc-3 ' ) , and Alrev(5'- ggNaRNgcRaaYtcDatNgg-3 ' ) ;
  • A2 (5 ' -gaRtggYtNggNccNgtNcaRga- 3 ' ) and A2rev (5 ' -cYKtcYtgNacNggNccNaRccaYtc-3 • ) were designed to match coding and non-coding DNA strands corresponding to amino acid sequences of two internal fragments of SopA obtained by the digestion of the protein with trypsin, D-S-P-I-E-F-A-L-P and E-W-L-G-P-V- Q-E-R, respectively.
  • oligonucleotide primer sequences represent amino acids. Thus where ⁇ Y' appears it means that the oligonucleotide primer sequence may comprise any codon which codes for tyrosine; where ⁇ W' appears it means that the oligonucleotide primer sequence may comprise any codon which codes for tryptophan etc. Al-A2rev and
  • Alrev-A2 combinations of primers were used in PCR in an attempt to amplify a sopA gene fragment using S. dublin 2229 chromosomal DNA as template.
  • the PCR reaction with Al-A2rev primers resulted in an approximately lkb DNA fragment.
  • This DNA fragment was cloned into pBluescript plasmid vector to yield pP80.
  • the cloned DNA fragment was labelled and used as a probe in a Southern blot to detect sopA-specific fragments in different restriction enzyme digests of S. dublin chromosomal DNA.
  • the sopA mutant of S. dublin was constructed as follows. An internal DNA fragment of sopA was amplified by PCR with the custom oligonucleotides SA1(5'- tgaagatatctcgaggcgcaattaat-3 ' ) and SA2(5'- taaggtgtttagatctttcggct-3 ' ) and was cloned into the suicide plasmid vector pDM4. The resulting plasmid was conjugated from E. coli S17.1 into S . dublin 2229 and Cml r transconjugants were obtained. One of these clones was denoted S. dublin SA1 and chosen for further experiments. The correct insertion of the suicide vector into the sopA gene was confirmed by PCR.
  • SopA has a role in the induction of enteritis
  • Salmonella-induced enteritis we assessed the ability of the different S. dublin strains to induce fluid secretion and PMN influx in ligated ileal loops in two calves. Compared with the wild-type strain the sopA mutant S . dublin SA1 " induced less fluid secretion and PMN influx (Fig 7) indicating that the SopA protein has a role in the induction of enteritis .
  • PA1 pipA :pPIPA
  • PD1 pipD :pPIPD
  • KIN copS : :pKIN

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

On prépare des micro-organismes atténués par mutation d'un ou de plusieurs gènes choisis parmi sopA, sopD, sipA, ou d'un gène tiré de l'îlot de pathogénicité SPI-5 lorsque le micro-organisme est Salmonella, ou d'un ou de plusieurs gènes homologues correspondant auxdits gènes de Salmonella, lorsque le micro-organisme est une autre entérobactérie. Par rapport aux souches de type sauvage, les micro-organismes présentent une entéropathogénicité réduite, mais sensiblement le même caractère envahissant. Ces micro-organismes atténués peuvent être administrés sous forme de vaccins contre les infections aux entérobactéries. L'invention concerne également les polypeptides codés par les gènes sopA, pipD, orfX, pipC, pipB et pipA, leurs variants, ainsi que les acides nucléiques codant ces polypeptides.
PCT/GB1999/000675 1998-03-06 1999-03-08 Attenuation de bacteries: matieres et methodes associees WO1999045120A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP99937942A EP1058732A2 (fr) 1998-03-06 1999-03-08 Attenuation de bacteries: matieres et methodes associees

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9804809.3 1998-03-06
GBGB9804809.3A GB9804809D0 (en) 1998-03-06 1998-03-06 Attenuated salmonella:materials and methods relating thereto

Publications (2)

Publication Number Publication Date
WO1999045120A2 true WO1999045120A2 (fr) 1999-09-10
WO1999045120A3 WO1999045120A3 (fr) 1999-12-16

Family

ID=10828124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000675 WO1999045120A2 (fr) 1998-03-06 1999-03-08 Attenuation de bacteries: matieres et methodes associees

Country Status (3)

Country Link
EP (1) EP1058732A2 (fr)
GB (1) GB9804809D0 (fr)
WO (1) WO1999045120A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030457A2 (fr) * 2000-10-12 2002-04-18 Washington University In St. Louis Microbes a mutation d'attenuation renfermant un terminateur de transcription
US7700104B2 (en) 1998-09-04 2010-04-20 Emergent Product Development Uk Limited Attenuated Salmonella SP12 mutants as antigen carriers
US7842290B2 (en) 1994-12-09 2010-11-30 Emergent Product Development Uk Limited Identification of genes
US7887816B2 (en) 1999-05-10 2011-02-15 Emergent Product Development Uk Limited Attenuated microorganisms for the treatment of infection
US8703153B2 (en) 2008-06-16 2014-04-22 Prokarium Ltd. Salmonella vectored vaccines against Chlamydia and methods of use
WO2015089268A1 (fr) * 2013-12-11 2015-06-18 University Of Massachusetts Compositions et procédés de traitement d'une maladie au moyen d'une protéine effectrice t3ss de salmonella (sipa)
CN106754594A (zh) * 2016-12-12 2017-05-31 扬州大学 一种猪霍乱沙门氏菌减毒载体菌及其构建方法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ABDELMOUNAAÏM ALLAOUI ET AL.: "Characterization of the Shigella flexneri ipgD and ipgF genes, which are located in the proximal part of the mxi locus" INFECTION AND IMMUNITY, vol. 61, no. 5, May 1993 (1993-05), pages 1707-1714, XP002108939 WASHINGTON US cited in the application *
CARMEN M. COLLAZO ET AL.: "The invasion-associated type-III protein secretion system in Salmonella - a review" GENE, vol. 192, no. 1, June 1997 (1997-06), pages 51-59, XP004115688 AMSTERDAM NL *
EDOUARD E. GALYOV ET AL.: "A secreted effector protein of Salmonella dublin is translocated into eukaryotic cells and mediates inflammation and fluid secretion in infected ileal mucosa" MOLECULAR MICROBIOLOGY, vol. 25, no. 5, September 1997 (1997-09), pages 903-912, XP002108937 cited in the application *
GUANGHUI WU ET AL.: "Mutants of Escherichia coli affected in respiration: the cloning and nucleotide sequence of ubiA, encoding the membrane-bound p-hydroxybenzoate:octaprenyltransferase" JOURNAL OF GENERAL MICROBIOLOGY, vol. 139, no. 8, August 1993 (1993-08), pages 1795-1805, XP002108936 *
HOWARD OCHMAN ET AL.: "Identification of a pathogenicity island required for Salmonella survival in host cells" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, no. 1, July 1996 (1996-07), pages 7800-7804, XP002094896 WASHINGTON US *
JACEK OSTROWSKI ET AL.: "Characterization of the cysJIH regions of Salmonella typhimorium and Escherichia coli B" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 264, no. 26, 15 September 1989 (1989-09-15), pages 15726-15737, XP002116160 MD US cited in the application *
JONES M A ET AL: "Secreted effector proteins of Salmonella dublin act in concert to induce enteritis." INFECTION AND IMMUNITY, (1998 DEC) 66 (12) 5799-804. JOURNAL CODE: GO7. ISSN: 0019-9567., XP002116161 United States *
MICHAEL W. WOOD ET AL.: "SopE, a secreted protein of Salmonella dublin, is translocated into the target eukaryotic cell via a sip-dependent mechanism and promotes bacterial entry" MOLECULAR MICROBIOLOGY, vol. 22, 1996, pages 327-338, XP002108938 cited in the application *
NINA K. HEINZINGER ET AL.: "Sequence analysis of the phs operon in Salmonella typhimurium and the contribution of thiosulfate reduction to anaerobic energy metabolism" JOURNAL OF BACTERIOLOGY, vol. 177, no. 10, May 1995 (1995-05), pages 2813-2820, XP002108935 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842290B2 (en) 1994-12-09 2010-11-30 Emergent Product Development Uk Limited Identification of genes
US7700104B2 (en) 1998-09-04 2010-04-20 Emergent Product Development Uk Limited Attenuated Salmonella SP12 mutants as antigen carriers
US7955600B2 (en) 1998-09-04 2011-06-07 Emergent Product Development Uk Limited Attenuated salmonella SP12 mutants as antigen carriers
US7887816B2 (en) 1999-05-10 2011-02-15 Emergent Product Development Uk Limited Attenuated microorganisms for the treatment of infection
WO2002030457A2 (fr) * 2000-10-12 2002-04-18 Washington University In St. Louis Microbes a mutation d'attenuation renfermant un terminateur de transcription
WO2002030457A3 (fr) * 2000-10-12 2003-01-23 Univ St Louis Microbes a mutation d'attenuation renfermant un terminateur de transcription
US8703153B2 (en) 2008-06-16 2014-04-22 Prokarium Ltd. Salmonella vectored vaccines against Chlamydia and methods of use
WO2015089268A1 (fr) * 2013-12-11 2015-06-18 University Of Massachusetts Compositions et procédés de traitement d'une maladie au moyen d'une protéine effectrice t3ss de salmonella (sipa)
US10201589B2 (en) 2013-12-11 2019-02-12 University Of Massachusetts Compositions and methods for treating disease using Salmonella T3SS effector protein (SipA)
US10835575B2 (en) 2013-12-11 2020-11-17 University Of Massachusetts Compositions and methods for treating disease using Salmonella T3SS effector protein (SipA)
CN106754594A (zh) * 2016-12-12 2017-05-31 扬州大学 一种猪霍乱沙门氏菌减毒载体菌及其构建方法

Also Published As

Publication number Publication date
WO1999045120A3 (fr) 1999-12-16
EP1058732A2 (fr) 2000-12-13
GB9804809D0 (en) 1998-04-29

Similar Documents

Publication Publication Date Title
Johnson et al. The role of a stress‐response protein in Salmonella typhimurium virulence
Vizcaíno et al. DNA polymorphism in the omp25/omp31 family of Brucella spp.: identification of a 1.7-kb inversion in Brucella cetaceae and of a 15.1-kb genomic island, absent from Brucella ovis, related to the synthesis of smooth lipopolysaccharide
Agin et al. Identification of a family of intimins common to Escherichia coli causing attaching-effacing lesions in rabbits, humans, and swine
US8021861B2 (en) Pathogenic Escherichia coli associated protein
CA2347849C (fr) Proteines omp85 de neisseria gonorrhoeae et de neisseria meningitidis, compositions renfermant lesdites proteines et methodes d'utilisation correspondantes
EP0540457A1 (fr) Améliorations dans le diagnostic et dans le prophylaxie de Borrelia burgdorferi
EP0650722A2 (fr) Particules d'invasion enrobées d'une protéine
JP2007289194A (ja) 空胞形成毒素欠損Ｈ．ｐｙｌｏｒｉおよび関連する方法
US8324354B2 (en) Environmentally regulated genes of Streptococcus suis
US7662588B2 (en) Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis, compositions containing same and methods of use thereof
Paton et al. Comparative toxicity and virulence of Escherichia coli clones expressing variant and chimeric Shiga-like toxin type II operons
US5874300A (en) Campylobacter jejuni antigens and methods for their production and use
KR20030032948A (ko) 독성 유전자, 단백질, 및 그 용도
SA98180918A (ar) تسلسلات حامض نووي وحامض أميني تتعلق ببكتيريا h.pylori " وتركيبات لقاحية منها "
ES2325911T3 (es) Fragmento genomico de streptococcus suis y usos clinicos del mismo.
WO1999045120A2 (fr) Attenuation de bacteries: matieres et methodes associees
AU6519090A (en) Conjugate vaccine for group B streptococcus
Thomas et al. Regulation of tcp genes in classical and E1 Tor strains of Vibrio cholerae O1
JPH09501308A (ja) 接触仲介性溶血素のレギュレーター
AU739191B2 (en) Vaccines containing attenuated bacteria
WO2000037493A2 (fr) Vaccin
Guidolin Molecular biology of" Vibrio cholerae" bacteriophage CP-T1 and its host interactions
Ustinovich et al. A Study of the IgA-Receptor Protein from a Group B Streptococcus
EP0594631A1 (fr) ANTIGENE DE MEMBRANE EXTERIEURE DE $i(BORDETELLA BRONCHISEPTICA)
JPH11225776A (ja) 新規ｓｐｏＩＩＩＥ

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): GB JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): GB JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1999937942

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09623550

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999937942

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999937942

Country of ref document: EP